Vir Biotechnology Past Earnings Performance
Past criteria checks 0/6
Vir Biotechnology has been growing earnings at an average annual rate of 28.3%, while the Biotechs industry saw earnings growing at 14.7% annually. Revenues have been growing at an average rate of 54.9% per year.
Key information
28.3%
Earnings growth rate
60.3%
EPS growth rate
| Biotechs Industry Growth | 12.9% |
| Revenue growth rate | 54.9% |
| Return on equity | -35.9% |
| Net Margin | -505.7% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Vir Biotechnology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 119 | -601 | 174 | 145 |
| 30 Jun 23 | 491 | -262 | 176 | 0 |
| 31 Mar 23 | 446 | -144 | 170 | 0 |
| 31 Dec 22 | 1,616 | 516 | 162 | 0 |
| 30 Sep 22 | 2,379 | 1,143 | 139 | 280 |
| 30 Jun 22 | 2,108 | 1,078 | 147 | 0 |
| 31 Mar 22 | 2,326 | 1,216 | 134 | 0 |
| 31 Dec 21 | 1,095 | 529 | 121 | 0 |
| 30 Sep 21 | 284 | -102 | 128 | 0 |
| 30 Jun 21 | 183 | -297 | 96 | 0 |
| 31 Mar 21 | 73 | -390 | 84 | 0 |
| 31 Dec 20 | 76 | -299 | 71 | 0 |
| 30 Sep 20 | 76 | -257 | 60 | 0 |
| 30 Jun 20 | 75 | -220 | 50 | 0 |
| 31 Mar 20 | 10 | -223 | 42 | 0 |
| 31 Dec 19 | 8 | -175 | 38 | 0 |
| 30 Sep 19 | 10 | -137 | 33 | 0 |
| 30 Jun 19 | 12 | -122 | 31 | 0 |
| 31 Mar 19 | 12 | -117 | 30 | 0 |
| 31 Dec 18 | 11 | -116 | 29 | 0 |
| 31 Dec 17 | 3 | -70 | 22 | 0 |
Quality Earnings: VIR * is currently unprofitable.
Growing Profit Margin: VIR * is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: VIR * is unprofitable, but has reduced losses over the past 5 years at a rate of 28.3% per year.
Accelerating Growth: Unable to compare VIR *'s earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VIR * is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-9.8%).
Return on Equity
High ROE: VIR * has a negative Return on Equity (-35.86%), as it is currently unprofitable.